Efficacy and safety of stereotactic radiotherapy in patients with HER2-positive breast cancer brain metastases following intracranial oligoprogression - Takeaways - MDSpire

Efficacy and safety of stereotactic radiotherapy in patients with HER2-positive breast cancer brain metastases following intracranial oligoprogression

  • By

  • Dongxing, Shen

  • Longyu, Zhu

  • Jun, Zhang

  • Deyou, Kong

  • Zhikun, Liu

  • May 31, 2026

  • 0 min

Share

  • 1

    This study evaluated the safety and effectiveness of salvage stereotactic radiotherapy (SRT) in HER2-positive breast cancer patients with brain metastases.

  • 2

    Forty patients with intracranial oligoprogression after TKI therapy were enrolled between January 2020 and January 2025.

  • 3

    The median post-radiotherapy intracranial progression-free survival was 6.4 months, with a median overall survival of 9.5 months.

  • 4

    Patients with MRI-stable disease had a significantly longer median progression-free survival compared to those with MRI-progressive disease.

  • 5

    The main grade ≥3 treatment-related adverse events included diarrhoea, anaemia, and leucopenia, with a low incidence of radiation necrosis.

Original Source(s)

Efficacy and safety of stereotactic radiotherapy in patients with HER2-positive breast cancer brain metastases following intracranial oligoprogression

  • by Dongxing, Shen , Longyu, Zhu , Jun, Zhang , Deyou, Kong , Zhikun, Liu

  • May 31, 2026

Related Content

Past present and future of radiosensitization in cervical cancer

Liquid Biopsy in Pediatric Acute Lymphoblastic Leukemia (ALL)

Antibody-drug conjugates in colorectal cancer: current landscape and future perspectives from clinical trials